This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABvac40

Araclon Biotech S.L.

Drug Names(s): amyloid beta peptide vaccine 40

Description: ABvac40 is an immunotherapy against the beta-amyloid 40 protein. The removal of this excess beta amyloid and pathological prevents the formation of amyloid plaques in the brain that produce neurodegeneration.

While few details have been released, we are assuming the therapy is a peptide drug based on the company's general research. We will update this record when new information becomes available.

Deal Structure: In March 2012, Grifols announced that they acquired 51% of the equity of Zaragoza-based company Araclon Biotech.

Partners: Grifols, S.A.


ABvac40 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug